Is This Biotech Stock a Bad News Buy?

Shares of biotech giant Biogen (NASDAQ: BIIB) have dropped by 40% in the past year, easily underperforming the broader market over this period. The drugmaker has encountered many headwinds related to its controversial Alzheimer's disease drug, Aduhelm.

But even though Biogen's stock is on sale, that doesn't necessarily make its shares a buy. Right now, the company's prospects still look dim. Let's look into what's going on with this biotech giant.

Continue reading

Source Fool.com